Injeção intravítrea de bevacizumab e gás C3F8 para tratamento da hemorragia submacular secundária a degeneração macular relacionada à idade: relato de casos

Submacular hemorrhage secondary to congenital toxoplasmosis

“…A study with intravitreal injection of C3F8 and bevacizumab, the same injection used in our case, reported good visual recovery, probably because it removed the blood in macular region, which decreases the toxicity to photoreceptors. ( 6 ) The blood in macular region that come in contact with photoreceptors leads to edema of these receptors after 1 hour of bleeding and causes the destruction of external nuclear layer in 2 weeks due to toxic effects of iron in the hemoglobin. ( 7 ) The objective of bevacizumab use is to reduce the vascular permeability that provokes an involution of subretinal neovascular membrane.…”

“…( 7 ) The objective of bevacizumab use is to reduce the vascular permeability that provokes an involution of subretinal neovascular membrane. ( 6 )…”